MX2021002382A - Sales y formas cristalinas de modulador alosterico positivo gabaa. - Google Patents
Sales y formas cristalinas de modulador alosterico positivo gabaa.Info
- Publication number
- MX2021002382A MX2021002382A MX2021002382A MX2021002382A MX2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A
- Authority
- MX
- Mexico
- Prior art keywords
- salts
- crystal forms
- positive allosteric
- allosteric modulator
- gabaa positive
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 2
- 239000013078 crystal Chemical group 0.000 title 1
- 229940126027 positive allosteric modulator Drugs 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725805P | 2018-08-31 | 2018-08-31 | |
| US16/517,369 US10562930B1 (en) | 2018-08-31 | 2019-07-19 | Salts and crystal forms of GABAA positive allosteric modulator |
| PCT/US2019/049103 WO2020047434A1 (en) | 2018-08-31 | 2019-08-30 | Salts and crystal forms of gabaa positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002382A true MX2021002382A (es) | 2021-08-11 |
Family
ID=69528249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002382A MX2021002382A (es) | 2018-08-31 | 2019-08-30 | Sales y formas cristalinas de modulador alosterico positivo gabaa. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10562930B1 (https=) |
| EP (2) | EP3710465B1 (https=) |
| JP (3) | JP7199739B2 (https=) |
| KR (1) | KR102845326B1 (https=) |
| CN (1) | CN113473991B (https=) |
| AU (1) | AU2019333310B8 (https=) |
| BR (1) | BR112021003727A2 (https=) |
| CA (1) | CA3111193A1 (https=) |
| IL (1) | IL281143B2 (https=) |
| MA (1) | MA50921A (https=) |
| MX (1) | MX2021002382A (https=) |
| TW (2) | TWI850138B (https=) |
| WO (1) | WO2020047434A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| KR20220157426A (ko) | 2020-03-25 | 2022-11-29 | 세이지 테라퓨틱스, 인크. | 호흡기 병태의 치료를 위한 작용제의 용도 |
| WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| JP2024506942A (ja) * | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| US20240207366A1 (en) | 2021-04-27 | 2024-06-27 | Kyungpook National University Industry-Academic Cooperation Foundation | Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| US20250170148A1 (en) * | 2022-02-28 | 2025-05-29 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| RU2194712C2 (ru) * | 1995-06-06 | 2002-12-20 | Коукенсис, Инк. | НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| CN1688288A (zh) * | 2002-08-05 | 2005-10-26 | 巴克斯特国际公司 | 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑 |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| WO2005007600A2 (en) | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
| WO2005016892A1 (en) | 2003-08-14 | 2005-02-24 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| RS51304B (sr) | 2005-06-09 | 2010-12-31 | Euro-Celtique S.A. | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| SG175330A1 (en) * | 2009-04-23 | 2011-11-28 | Theravance Inc | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY |
| US8377929B2 (en) * | 2010-02-24 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same |
| CA2817290A1 (en) * | 2010-11-11 | 2012-05-18 | Josef Penninger | Compounds and methods for treating pain |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| HUE037122T2 (hu) | 2013-07-24 | 2018-08-28 | Commissariat Energie Atomique | Flekainid alkalmazása anti-konnexin szerként és eljárás pszichotróp farmakon hatásainak fokozására |
| KR102516745B1 (ko) * | 2014-08-01 | 2023-03-31 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| AU2019406803B2 (en) | 2018-12-17 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2020231506A1 (en) | 2019-03-04 | 2021-09-30 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
| WO2020185710A1 (en) | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
| US20220265666A1 (en) | 2019-08-02 | 2022-08-25 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| EP4041226A1 (en) | 2019-10-02 | 2022-08-17 | Praxis Precision Medicines, Inc. | Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists |
| WO2021168106A1 (en) | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| WO2022006541A1 (en) | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| JP2023539125A (ja) | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP2024506942A (ja) | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| CN117715641A (zh) | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| WO2023159094A2 (en) | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| EP4514357A4 (en) | 2022-04-26 | 2026-04-29 | Praxis Prec Medicines Inc | Methods for the treatment of neurological disorders |
-
2019
- 2019-07-19 US US16/517,369 patent/US10562930B1/en active Active
- 2019-08-30 JP JP2020517339A patent/JP7199739B2/ja active Active
- 2019-08-30 TW TW112141287A patent/TWI850138B/zh active
- 2019-08-30 WO PCT/US2019/049103 patent/WO2020047434A1/en not_active Ceased
- 2019-08-30 KR KR1020217009437A patent/KR102845326B1/ko active Active
- 2019-08-30 MX MX2021002382A patent/MX2021002382A/es unknown
- 2019-08-30 BR BR112021003727-6A patent/BR112021003727A2/pt unknown
- 2019-08-30 CA CA3111193A patent/CA3111193A1/en active Pending
- 2019-08-30 EP EP19842855.9A patent/EP3710465B1/en active Active
- 2019-08-30 CN CN201980071246.9A patent/CN113473991B/zh active Active
- 2019-08-30 IL IL281143A patent/IL281143B2/en unknown
- 2019-08-30 TW TW108131297A patent/TWI823999B/zh active
- 2019-08-30 EP EP24194131.9A patent/EP4458357A3/en active Pending
- 2019-08-30 MA MA050921A patent/MA50921A/fr unknown
- 2019-08-30 AU AU2019333310A patent/AU2019333310B8/en active Active
- 2019-11-27 US US16/698,057 patent/US10927141B2/en active Active
-
2021
- 2021-01-07 US US17/143,602 patent/US20220024967A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199092A patent/JP2023036708A/ja active Pending
-
2023
- 2023-12-05 US US18/529,117 patent/US12404297B2/en active Active
-
2024
- 2024-10-03 JP JP2024174009A patent/JP2025020120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002382A (es) | Sales y formas cristalinas de modulador alosterico positivo gabaa. | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| JOP20250289A1 (ar) | صور بلورية جديدة | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| BR112017003421A2 (pt) | formas sólidas cristalinas de 6-carbóxi-2-(3,5-diclorofenil)-benzoxazol | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2018010983A (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| EA202090486A2 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| EA201790892A1 (ru) | Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина | |
| EP4606784A3 (en) | Co-crystals, salts and solid forms of tenofovir alafenamide | |
| BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| PH12020550133A1 (en) | Crystal forms of immunomodulators | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| AR107547A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| CL2017003475A1 (es) | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. |